Terminated PHASE2 INTERVENTIONAL 2-arm NCT00006371

A Phase II Trial of Early Medical Adrenalectomy for D0.5 Prostate Cancer

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Interventions aminoglutethimide ketoconazole therapeutic hydrocortisone

Updated 6 times since 2017 Last updated: Sep 25, 2012 Started: May 31, 2000 Primary completion: Dec 31, 2001 Completion: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low accrual

Other terminated trials from H. Lee Moffitt Cancer Center and Research Institute

See all terminations from H. Lee Moffitt Cancer Center and Research Institute

Other Prostate Cancer trials with similar outcome

Browse all Prostate Cancer trials

Listed as NCT00006371, this PHASE2 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by H. Lee Moffitt Cancer Center and Research Institute, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

May 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lee Moffitt Cancer Center and Research Institute
Janssen Pharmaceuticals
National Cancer Institute (NCI)

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States